Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival

Loading news article.

Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival | WAPE

Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival

Article summary

Related companies

Comments —